The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Harbour BioMed brings advanced antibody discovery platforms to the table
The move strengthens GBL’s clinical-stage presence in the United States
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Subscribe To Our Newsletter & Stay Updated
